SRPT Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Sarepta Therapeutics, Inc. had $2.2B of revenue in fiscal 2025, up 15.6% on the year before. Over five years, revenue changed +32.4% a year on average.
Last close Β· Oct 23, 2026
$17.73
2.5%Hi! I read Sarepta Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+15.6%
Yes. Sales grew 15.6% last year.
Does it make a profit?
β32.5%
No. It lost money last year.
Does profit turn into cash?
β14.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Sarepta Therapeutics, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 5, 2026
Thursday Β· in 10 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 5, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 6, 2026 | Q1 '26 | After the market closes | 8-K β |
| Jan 12, 2026 | Q4 '25 | During market hours | 8-K β |
| Nov 3, 2025 | Q3 '25 | After the market closes | 8-K β |
| Jul 14, 2025 | Q2 '25 | Time not announced | 8-K β |
| May 6, 2025 | Q1 '25 | After the market closes | 10-Q β |
| Jan 13, 2025 | Q4 '24 | During market hours | 8-K β |
| Nov 6, 2024 | Q3 '24 | After the market closes | 10-Q β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Sarepta Therapeutics, Inc. had $2.2B of revenue in fiscal 2025, up 15.6% on the year before. Over five years, revenue changed +32.4% a year on average. Its operating margin was β31.8%, down 43.3Β pts: of every 100 in sales, about β32 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Sarepta Therapeutics, Inc. lost $713M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$307M in fiscal 2025, β14.0% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· Sarepta Therapeutics, Inc. returned $25.0M to shareholders in fiscal 2025. The diluted share count fell 7.2%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Sarepta Therapeutics, Inc. has $111M more cash than debt.
Cash, debt and the ratios that show how comfortably Sarepta Therapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $2.1B | $2.0B | $1.7B | $1.4B | $940M |
| Debt incl. finance leases | $564M | $1.5B | $1.2B | $1.1B | $829M |
| Net debt / EBITDA | β | β | β | β0.9x | β |
| Debt / equity | 0.6x | 4.0x | 1.4x | 0.7x | 0.7x |
| Interest coverage | β7.2x | β | β | β | β |
| Current ratio | 5.8x | 4.1x | 3.9x | 4.2x | 2.3x |
| Quick ratio | 5.3x | 3.8x | 3.5x | 3.2x | 1.5x |
| Total assets | $3.1B | $3.1B | $3.3B | $4.0B | $3.3B |
| Total liabilities | $2.2B | $2.7B | $2.4B | $2.4B | $2.2B |
| Shareholders' equity | $928M | $385M | $859M | $1.5B | $1.1B |
| Net debt (β = net cash) | β$1.6B | β$445M | β$438M | β$218M | β$111M |
KIRA Β· Its return on capital was β53.7%: every 100 invested in the business earned about β54 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Sarepta Therapeutics, Inc. passes 4 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 8 | 2 / 8 | 2 / 7 | 4 / 7 | 2 / 7 | 2 / 8 | 4 / 8 | 5 / 8 | 4 / 8 |
| Accruals ratio | β5.1% | 20.9% | 1.8% | β14.9% | β27.5% | 0.8% | β12.0% | β1.1% | 12.2% | β13.9% |
| Altman Z'' | β4.54 | 3.40 | 2.24 | β1.52 | 0.53 | 0.62 | β1.01 | β0.75 | 1.44 | β2.78 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $5.4M | $155M | $301M | $381M | $540M | $702M | $933M | $1.2B | $1.9B | $2.2B |
| Gross profit | $5.3M | β | β | β | β | β | β | β | β | $2.2B |
| Research and development | $188M | $167M | $402M | $561M | $722M | $771M | $877M | $877M | $805M | $1.5B |
| Operating income | β$267M | β$172M | β$344M | β$706M | β$564M | β$460M | β$536M | β$268M | $218M | β$700M |
| Interest expense | $1.9M | $5.8M | $33.7M | $30.7M | $59.9M | $63.5M | β$53.2M | β$22.0M | β$18.4M | β$38.1M |
| Pretax income | β$267M | β$48.6M | β$363M | β$714M | β$553M | β$419M | β$690M | β$520M | $261M | β$702M |
| Income tax | β | $2.1M | β$0.7M | $1.2M | $1.1M | β$0.2M | $13.5M | $15.9M | $25.5M | $11.2M |
| Net income | β$267M | β$50.7M | β$362M | β$715M | β$554M | β$419M | β$703M | β$536M | $235M | β$713M |
| Net income to common | β | β | β | β | β | β | β | β$536M | $235M | β$713M |
| Diluted EPS | β$5.49 | β$0.86 | β$5.46 | β$9.71 | β$7.11 | β$5.15 | β$8.03 | β$5.80 | $2.34 | β$7.13 |
| Diluted shares | 0.05B | 0.06B | 0.07B | 0.07B | 0.08B | 0.08B | 0.09B | 0.09B | 0.11B | 0.10B |
| Cash flow | ||||||||||
| Cash from operations | β$246M | β$232M | β$389M | β$456M | $107M | β$443M | β$325M | β$501M | β$206M | β$205M |
| Capital expenditure | $5.3M | $12.0M | $61.2M | $59.6M | $82.2M | $38.5M | $30.8M | $76.1M | $137M | $102M |
| Free cash flow | β$251M | β$244M | β$450M | β$516M | $25.3M | β$482M | β$356M | β$577M | β$343M | β$307M |
| Depreciation and amortization | $5.6M | $8.1M | $12.2M | $24.5M | $26.9M | $38.0M | $41.9M | $44.4M | $37.7M | $44.5M |
| Stock-based compensation | $30.0M | $30.5M | $50.1M | $78.6M | $108M | $114M | $233M | $183M | $184M | $123M |
| Acquisitions | β | β | β | $173M | β | β | β | β | β | β |
| Share buybacks | β | β | β | β | β | β | β | $0.0M | $0.0M | $25.0M |
| Dividends and buybacks | β | β | β | β | β | β | β | $0.0M | $0.0M | $25.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $318M | $1.1B | $1.2B | $1.1B | $1.9B | $2.1B | $2.0B | $1.7B | $1.4B | $940M |
| Total debt | $17.7M | $431M | $421M | β | β | $564M | $1.5B | $1.2B | $1.1B | $829M |
| Current assets | $373M | $1.2B | $1.4B | $1.5B | $2.5B | $2.6B | $2.6B | $2.6B | $3.1B | $2.5B |
| Current liabilities | $75.4M | $88.3M | $174M | $265M | $416M | $453M | $620M | $654M | $732M | $1.1B |
| Inventory | $12.8M | $83.6M | $125M | $171M | $232M | $186M | $204M | $323M | $750M | $915M |
| Property and equipment, net | $37.8M | $43.2M | $97.0M | $130M | $190M | $191M | $180M | $227M | $340M | $345M |
| Intangible assets | $8.1M | $14.4M | $11.6M | $12.5M | $13.6M | $14.2M | $7.6M | $29.6M | $26.9M | $28.9M |
| Total assets | $424M | $1.3B | $1.6B | $1.8B | $3.0B | $3.1B | $3.1B | $3.3B | $4.0B | $3.3B |
| Total liabilities | $87.4M | $519M | $610M | $1.0B | $2.2B | $2.2B | $2.7B | $2.4B | $2.4B | $2.2B |
| Preferred stock | β | β | β | β | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $337M | $789M | $1.0B | $818M | $762M | $928M | $385M | $859M | $1.5B | $1.1B |
| Margins | ||||||||||
| Gross margin | 97.6% | β | β | β | β | β | β | β | β | 98.8% |
| Operating margin | β4,920.3% | β111.0% | β114.1% | β185.3% | β104.5% | β65.5% | β57.5% | β21.5% | 11.5% | β31.8% |
| EBITDA margin | β4,816.8% | β105.8% | β110.1% | β178.8% | β99.5% | β60.1% | β53.0% | β18.0% | 13.4% | β29.8% |
| Net margin | β4,930.2% | β32.8% | β120.2% | β187.8% | β102.6% | β59.7% | β75.4% | β43.1% | 12.4% | β32.5% |
| FCF margin | β4,633.1% | β157.8% | β149.4% | β135.5% | 4.7% | β68.6% | β38.2% | β46.4% | β18.0% | β14.0% |
| Returns | ||||||||||
| Return on capital | β577.1% | β96.0% | β97.3% | β | β | β | β | β50.2% | 15.0% | β53.7% |
| Return on capital employed | β76.5% | β14.1% | β23.4% | β45.3% | β22.0% | β17.1% | β21.4% | β10.3% | 6.7% | β31.0% |
| Return on equity | β79.4% | β9.0% | β39.7% | β77.3% | β70.1% | β49.6% | β107.2% | β86.2% | 19.7% | β53.5% |
| Return on assets | β63.0% | β5.9% | β24.5% | β41.3% | β23.1% | β13.7% | β22.4% | β16.8% | 6.5% | β19.5% |
| Return on tangible equity | β81.3% | β6.5% | β35.5% | β88.8% | β74.1% | β45.8% | β186.4% | β64.6% | 15.7% | β64.2% |
| Growth | ||||||||||
| Revenue growth | β | 2,751.6% | 94.7% | 26.5% | 41.8% | 30.0% | 32.9% | 33.3% | 53.0% | 15.6% |
| Net income growth | β | β | β | β | β | β | β | β | β | β403.3% |
| EPS growth | β | β | β | β | β | β | β | β | β | β404.7% |
| FCF growth | β | β | β | β | β | β2,006.5% | β | β | β | β |
| Share count change | β | 20.8% | 12.6% | 11.1% | 5.9% | 4.2% | 7.7% | 5.5% | 16.8% | β7.2% |
| Financial health | ||||||||||
| Net debt / EBITDA | β | β | β | β | β | β | β | β | β0.9x | β |
| Debt / equity | 0.1x | 0.5x | 0.4x | β | β | 0.6x | 4.0x | 1.4x | 0.7x | 0.7x |
| Interest coverage | β141.0x | β29.6x | β10.2x | β23.0x | β9.4x | β7.2x | β | β | β | β |
| Current ratio | 5.0x | 13.9x | 8.2x | 5.5x | 6.0x | 5.8x | 4.1x | 3.9x | 4.2x | 2.3x |
| Quick ratio | 4.8x | 13.0x | 7.5x | 4.9x | 5.4x | 5.3x | 3.8x | 3.5x | 3.2x | 1.5x |
| Capital allocation | ||||||||||
| Capex / revenue | 98.5% | 7.8% | 20.3% | 15.7% | 15.2% | 5.5% | 3.3% | 6.1% | 7.2% | 4.6% |
| Stock comp / revenue | 552.7% | 19.7% | 16.7% | 20.6% | 20.0% | 16.2% | 25.0% | 14.7% | 9.7% | 5.6% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 2.0 | 2.0 | 4.0 | 2.0 | 2.0 | 4.0 | 5.0 | 4.0 |
| Altman Z'' | β4.5 | 3.4 | 2.2 | β1.5 | 0.5 | 0.6 | β1.0 | β0.7 | 1.4 | β2.8 |
| Accruals ratio | β5.1% | 20.9% | 1.8% | β14.9% | β27.5% | 0.8% | β12.0% | β1.1% | 12.2% | β13.9% |
Source: SEC EDGAR XBRL filings (CIK 0000873303). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
